Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Creelan BC, et al.
Nature Medicine
August 2021
Authors and Affiliates
Benjamin C Creelan #,1, Chao Wang #,2, Jamie K Teer 3, Eric M Toloza 2, Jiqiang Yao 3, Sungjune Kim 4, Ana M Landin 5, John E Mullinax 6, James J Saller 7, Andreas N Saltos 2, David R Noyes 4, Leighann B Montoya 8, Wesley Curry 8, Shari A Pilon-Thomas 4, Alberto A Chiappori 2, Tawee Tanvetyanon 2, Frederic J Kaye 9, Zachary J Thompson 2, Sean J Yoder 10, Bin Fang 10, John M Koomen 10, Amod A Sarnaik 2, Dung-Tsa Chen 3, Jose R Conejo-Garcia 2, Eric B Haura #,2, Scott J Antonia #,11;
1 Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. ben.creelan@moffitt.org.
2 Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
3 Department of Bioinformatics and Biostatistics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
4 Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
5 Cell Therapy Facility, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
6 Department of Sarcoma, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
7 Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
8 Immune and Cellular Therapy Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
9 Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
10 Chemical Biology & Molecular Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
11 Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
# Contributed equally.